Medical Research Collaborative will release this morning a 211 page short report on Amarin. Medical Research Collaborative is a “collaborative effort, bringing together expertise from various fields of scientific endeavor, as well as in foreign and domestic patent law and regulatory science,” according to its website. Shares of Amarin have risen over 700% since the company reported positive results from its REDUCE-IT trial in September of 2018, but “lingering doubts as to the effectiveness of the therapy remain,” contends Medical Research in a summary of the report.
There remains the possibility that mineral oil had an adverse effect on the performance of the placebo group by hindering drug absorption, the firm claims. Further, it assails Amarin’s patent portfolio for Vascepa, saying each claim is “invalidated by prior art or otherwise not infringed by ANDA filers.” Shares of Amarin are down 12c to $20.17 in premarket trading. The stock closed Wednesday down 2% to $20.83.